CRISPR Therapeutics AG — Q1 2024 10-Q
Reporting period: Three months ended March 31, 2024. Unaudited consolidated financial statements prepared under U.S. GAAP.
Business context
CRISPR Therapeutics develops CRISPR/Cas9-based therapies. CASGEVY, its gene-edited therapy developed with Vertex, had received approvals in the U.S. and several other countries for eligible patients with sickle cell disease or transfusion-dependent beta thalassemia. The company reported no product-sales revenue in the quarter. Its other programs span cell therapies, in vivo editing and type 1 diabetes.
Financial results and liquidity
| Metric | Q1 2024 | Q1 2023 |
|---|---|---|
| Revenue | $0.5 million | $100.0 million |
| Research and development expense | $76.2 million | $99.9 million |
| General and administrative expense | $18.0 million | $22.4 million |
| Collaboration expense, net | $47.0 million | $42.2 million |
| Operating loss | $140.6 million | $64.5 million |
| Other income, net | $24.7 million | $12.7 million |
| Net loss | $116.6 million | $53.1 million |
| Net loss per share, diluted | $1.43 | $0.67 |
- Cash, cash equivalents and marketable securities totaled $2.108 billion at March 31, 2024, versus $1.696 billion at December 31, 2023. Total assets were $2.439 billion; total liabilities were $355.1 million. The filing does not report borrowings or debt.
- Operating cash flow was positive $109.8 million, compared with $8.8 million in Q1 2023. This was substantially affected by collection of the $200 million Vertex milestone receivable recorded at year-end 2023; it should not be read as a measure of recurring operating cash generation.
- Investing cash flow was negative $97.8 million and financing cash flow was positive $305.9 million. Financing included approximately $279.0 million net proceeds from a February registered direct offering.
- Operating margins are not meaningfully comparable given minimal revenue and the company’s R&D-stage business model.
Material changes versus prior year
- Revenue fell by $99.5 million: Q1 2023 included a $100 million Vertex upfront payment under the diabetes-related license arrangement; Q1 2024 had no collaboration revenue and $0.5 million of grant revenue.
- Net loss increased by $63.5 million, principally reflecting the absence of the prior-year upfront revenue, despite lower R&D and G&A expense. Other income rose by $12.0 million, mainly due to interest income.
- R&D expense declined $23.8 million, primarily due to lower external research/manufacturing and facility costs. Net CASGEVY collaboration expense rose $4.8 million, primarily due to commercial and manufacturing costs.
- Cash and investments increased, supported in part by the share offering and collection of the Vertex milestone. Shares outstanding increased during the quarter; the offering issued approximately 3.93 million shares.
Outlook, risks and notable items
- Management expects existing cash to fund operating expenses and capital expenditures for at least 24 months, excluding additional Vertex proceeds and future capital raises. The estimate depends on assumptions and actual cash use could be faster.
- The company expects continued losses and substantial R&D spending, and states it will need additional capital for long-term development. Future equity or debt financing may dilute shareholders or have unfavorable terms; collaboration financing could require giving up rights.
- Under the Vertex arrangement, CASGEVY net profits and losses are allocated 40% to CRISPR Therapeutics and 60% to Vertex. The company reported $4.0 million of 2024 CASGEVY costs deferred under the agreement; deferred costs are recoverable by Vertex from future program profitability, subject to contractual limits.
- Development and commercial milestones and royalties under collaboration agreements remain contingent and, where applicable, constrained from revenue recognition. The filing cites clinical, regulatory, manufacturing, market-acceptance and intellectual-property uncertainties.
- Management reported no material changes to previously disclosed risk factors and no pending legal claims it believes are likely to have a material adverse effect. Disclosure controls were assessed as effective at the reasonable-assurance level.
Investor verification priorities
- Track CASGEVY patient access, commercialization, sales and the resulting 40% share of program economics.
- Reconcile operating cash flow with the one-time $200 million milestone collection and monitor recurring cash burn against the stated 24-month runway.
- Review progress, safety and timelines for CTX112, CTX131, CTX310, CTX320 and CTX211, including planned or ongoing trials.
- Monitor deferred CASGEVY costs, contingent milestone obligations and potential future financing or dilution.
- Confirm future revenue sources: the company had no product-sales revenue in Q1 2024, and many potential milestones and royalties remain dependent on uncertain events.